– Doubled the market opportunity for Treprostinil Injection by adding subcutaneous delivery – Resubmitted New Drug Application for LIQ861 (treprostinil) Inhalation Powder – Improved financial position with private placement and access to new credit facility – Company to host webcast and conference call today at 8:30 a.m. ET MORRISVILLE, N.C., May […]
Other News
Acutus Medical Reports First Quarter 2021 Financial Results
CARLSBAD, Calif., May 12, 2021 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the first quarter of 2021. Recent Highlights: Reported revenue of $3.6 million in the […]
Nuwellis Provides More Children in Texas With Access to Its Unique Fluid Management Technology
Gentle Ultrafiltration with Aquadex SmartFlow® Expands Options for Pediatric Patients EDEN PRAIRIE, Minn., May 13, 2021 (GLOBE NEWSWIRE) — Reaffirming its commitment to expanding access to life-saving ultrafiltration therapies for adult and pediatric patients suffering from fluid overload, Nuwellis, Inc. (Nasdaq: NUWE), formerly CHF Solutions, Inc., today announced that its […]
ZOLL Medical Receives FDA IDE Approval for Initiation of ISO Shock (Incorporating Supersaturated Oxygen in Shock) Feasibility Study
Study Evaluates the Safety and Feasibility of TherOx Supersaturated Oxygen (SSO2) Therapy in STEMI Patients presenting with Cardiogenic Shock CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today the U.S. Food and Drug Administration (FDA) has approved an investigational device […]
Galaxy Medical and Japan Lifeline Enter Distribution Agreement For Novel Pulsed Electric Field Focal Ablation Catheter
SAN CARLOS, Calif., May 12, 2021 /PRNewswire/ — Galaxy Medical (Galaxy) and Japan Lifeline (JLL) today announced an exclusive distribution agreement for the ALPHA1 ablation catheter in the United States, developed by Japan Lifeline for use with the Galaxy CENTAURI™ Pulsed Electric Field (PEF) System. Under the terms of the agreement, Galaxy will pursue US […]
ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update
Topline data from Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 anticipated in the third quarter of 2021 WESTMINSTER, Colo., May 11, 2021 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today […]
scPharmaceuticals Inc. Reports First Quarter 2021 Financial Results and Provides Business Update
FREEDOM clinical study on track for topline results in Q3 2021 Ended Q1 with cash, cash equivalents, restricted cash and investments of $96.5 million BURLINGTON, Mass., May 12, 2021 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to […]
InspireMD Announces Appointment of Katie Arnold to Board of Directors
TEL AVIV, Israel, May 12, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced it has appointed seasoned marketing executive Kathryn (Katie) Arnold to its Board of Directors. […]
Caladrius Biosciences Receives $1.4 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program
BASKING RIDGE, N.J., May 12, 2021 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that it has received $1.4 million in non-dilutive funding as an approved participant of the […]
Shifa Launches with Seed Financing to Address Cardiovascular Disease by Developing Orally Bioavailable Drugs for the Treatment of Dyslipidemia
– Collaboration with Xontogeny provides funding and key advisory support for early development – MALVERN, Pa.–(BUSINESS WIRE)–Shifa Biomedical Corporation (Shifa), a drug discovery company developing an oral small molecule PCSK9/low density lipoprotein-cholesterol receptor (LDLR) antagonist, P-21, to treat dyslipidemia, today announced their launch with a seed investment from Xontogeny, LLC […]



